Literature DB >> 1478951

Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells.

T W Grunt1, C Somay, H Oeller, E Dittrich, C Dittrich.   

Abstract

HOC-7 malignant ovarian surface epithelial cells have been exposed to differentiation promoters like dimethyl sulfoxide (DMSO) and retinoic acid (RA) and the resulting cell phenotypes were characterized immunologically. Immunocytochemistry revealed that DMSO caused elevation of membrane-associated staining for epidermal growth factor-receptor (EGF-R) and for desmoplakins I and II (DPI+II). DMSO also stimulated cytoplasmic and surface labelling for CA 125 and extracellular deposition of fibronectin (FN). A fixed-cell ELISA system was used for quantification of these differentiation-like responses and revealed that DMSO efficiently induced expression of EGF-R, CA 125, FN and DPI+II in dose-dependent manner. Immunocytochemistry, ELISA and Western blotting additionally demonstrated that both DMSO and RA caused down-regulation of myc oncoproteins. Densitometer evaluation of electrophoresed proteins revealed a 50% DMSO- and a 25% RA-induced myc reduction. Apart from growth reduction, which was seen for both inducers, inhibition of myc gene expression was the only response of HOC-7 cells to RA-treatment. The extent of myc down-regulation seems, therefore, to be crucial for the initiation of maturational processes in the cells. Subsequent phenotypic differentiation of HOC-7 cells causes elevated levels of EGF-R, CA 125, FN and DPI+II. This cell model might be useful for the distinction between induced growth reduction and differentiation of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478951     DOI: 10.1242/jcs.103.2.501

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  8 in total

Review 1.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

2.  Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status.

Authors:  C D Katsetos; I Stadnicka; J C Boyd; H Ehya; S Zheng; C M Soprano; H S Cooper; A S Patchefsky; D R Soprano; K J Soprano
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

3.  Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.

Authors:  Karin Bauer; Anna S Berghoff; Matthias Preusser; Gerwin Heller; Christoph C Zielinski; Peter Valent; Thomas W Grunt
Journal:  Am J Cancer Res       Date:  2021-02-01       Impact factor: 6.166

4.  Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription.

Authors:  H Harant; I Korschineck; G Krupitza; B Fazeny; C Dittrich; T W Grunt
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

5.  Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.

Authors:  G Krupitza; R Fritsche; E Dittrich; H Harant; H Huber; T Grunt; C Dittrich
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

6.  Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.

Authors:  E Dittrich; M Offterdinger; S M Schneider; Ch Dittrich; H Huber
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

7.  Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells.

Authors:  Karin Bauer; Daniela Berger; Christoph C Zielinski; Peter Valent; Thomas W Grunt
Journal:  Oncotarget       Date:  2018-05-29

8.  Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.

Authors:  Thomas W Grunt; Astrid Slany; Mariya Semkova; Ramón Colomer; María Luz López-Rodríguez; Michael Wuczkowski; Renate Wagner; Christopher Gerner; Gerald Stübiger
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.